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Headache is a public health problem
of enormous scope that has an impact
on the sufferer and on society [1].
Headache includes a group of disor-
ders characterised by recurrent
episodes of head pain and associated
symptoms. The most common prima-
ry headaches are tension-type
headache and migraine, for which a
lifetime prevalence of 78% and 16%
has been reported, respectively [2].
Other primary headaches, such as
cluster headache, are rare, and usual-
ly affect less than 1% of the popula-
tion. Tension-type headache and
migraine result in important direct
and indirect costs, considering that
these disorders affect adults in their
most productive ages of around
20–50 years.
The study of Karl› et al. [3] consti-
tutes a cost analysis of primary
headaches in Turkey based on a large
sample of patients derived from a
national survey. In a recent review of
cost estimations of migraine per
patient performed in Europe [4], only
6 studies have estimated the annual
cost of migraine per patient [5–12]
(see Fig. 1). The cost of migraine per
patient in Turkey is considerably
lower compared with other European
countries, but substantial variations
across countries are clearly observed
(Fig. 1). The reason for this wide
range lies in different methodological
approaches and in different years of
costing. Another factor contributing to
cross-country variations is differences
in the national health care systems,
where for example cost constraints
may lead a focus on less expensive
management strategies in some coun-
tries. Some particularities are remark-
able in this group of European stud-
ies. The oldest cost estimation is the
Swedish study, performed in 1991
[11]. Although this study found a sim-
ilar cost to the Turkey study, it is not
comparable due to the year of the cost
estimation and the lack of use of the
International Headache Criteria
(IHC). Before the Turkish study, the
most recent was the German study
performed in 2000 [12]. This study
calculated the cost to be approximate-
ly 7 times that in the Turkish study
but methodologically used gross
domestic income rather than average
salary levels as a basis for calculating
indirect costs, which could lead to an
overestimation of these costs, in con-
trast with the Turkish study where the
estimation was based on the minimum
wage. The studies from the UK [10]
and the Netherlands [5] used surveys
to calculate the cost of migraine per
patient, as did the Turkish study. The
longer recall period of 12 months
used in the UK study compared with
three months in the study in the
Netherlands was suggested as the
explanation of the high cost of
migraine in the UK. Although the
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Turkish study used a recall of 12
months, the costs are still lower com-
pared with these 2 countries. The high
cost of migraine in these two coun-
tries compared with Turkey is proba-
bly explained due to the higher cost
of medical attention rather than being
related with methodological issues.
Finally, the indirect costs in the
Spanish and French studies were
based on working population and
work absence, respectively [6, 7]. In
both studies it was suggested that the
cost could be overestimated consider-
ing the lack of analysis of the non-
working population. The Turkish
study analysed working and non-
working populations, with consider-
ably lowered costs. Again the higher
cost of medical attention in these
countries compared with Turkey may
explain the differences.
The study of Karli et al. [3] is partic-
ular in some aspects. First, the lower
annual cost of primary headaches per
patient is remarkable compared with
other European countries. The
authors mention that the lower direct
cost in Turkey is based on the cheap-
ness of the cost of diagnostic and
treatment tools in Turkey and the
lower tendency of Turkish patients to
seek medical care. This asseveration
is probably true, but other aspects are
important to mention, for example
the indirect cost calculation was
based on the minimum wage in
Turkey, being lower compared with
other European countries. On the
other hand, it is interesting how the
Turkish population has less loss of
productivity than other countries
related with headache events, maybe
explained by sociocultural aspects.
The lower loss of productivity obvi-
ously has an impact on indirect costs
of migraine and other types of
headache. Finally, one of the most
important contributions of the present
study is the cost estimation of the dif-
ferent types of primary headaches. In
general, it is hypothesised that the
other types of headache such as ten-
sion-type headache could have higher
costs than migraine, as they affect a
significantly large proportion of the
total population and are related to
high work absence rates [4]. This
hypothesis is not supported by the
study of Karli et al. [3], where
patients with migraine had the high-
est annual cost per patient compared
with the other types of headache.
Further investigations are required
but the current study constitutes use-
ful evidence for future research.
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Fig. 1 Total annual cost of
migraine per patient in
seven European countries.
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